PRAC meeting highlights 30 September - 3 October 2024

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee (PRAC) is responsible for assessing and monitoring safety issues for human medicines.

The current PRAC highlights from the Sept-Oct 2024 meeting describes the review of medicines containing finasteride and dutasteride started and describes new safety information for healthcare professionals concerning the risk of medication errors due to change of dosing syringe for Keppra and Levetiracetam UCB oral solution.